Antonis Kattamis

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4874584/publications.pdf

Version: 2024-02-01

180 papers	6,288 citations	87843 38 h-index	76872 74 g-index
180 all docs	180 docs citations	180 times ranked	5735 citing authors

#	Article	IF	Citations
1	Fish evaluation of additional cytogenetic aberrations and hyperdiploidy in childhood Burkitt lymphoma. Leukemia and Lymphoma, 2022, 63, 551-561.	0.6	1
2	Immune response and adverse events after vaccination against <scp>SARSâ€CoV</scp>â€2 in adult patients with transfusionâ€dependent thalassaemia. British Journal of Haematology, 2022, 197, 576-579.	1.2	6
3	Heterozygosity of the Complex Corfu Î´0Î²+ Thalassemic Allele (HBD Deletion and HBB:c.92+5G>A) Revisited. Biology, 2022, 11, 432.	1.3	1
4	Brachytherapy for Pediatric Patients at Gustave Roussy Cancer Campus: A Model of International Cooperation for Highly Specialized Treatments. International Journal of Radiation Oncology Biology Physics, 2022, 113, 602-613.	0.4	11
5	The safety and acceptability of twiceâ€daily deferiprone for transfusional iron overload: A multicentre, openâ€label, phase 2 study. British Journal of Haematology, 2022, 197, .	1.2	8
6	A national study of antibiotic use in Greek pediatric hematology oncology and bone marrow transplant units. Antimicrobial Stewardship & Healthcare Epidemiology, 2022, 2, .	0.2	2
7	The The use of oral glucose-lowering agents (GLAs) in Î²-thalassemia patients with diabetes: Preliminary data from a retrospective study of ICET-A Network.. Acta Biomedica, 2022, 93, e2022162.	0.2	1
8	HGG-53. "Profile of High Grade Gliomas and Diffuse Intrinsic Pontine Gliomas in Greek Pediatric Patients: an 8-year Single Institution's experience". Neuro-Oncology, 2022, 24, i73-i74.	0.6	0
9	PATH-13. Methylation analysis in the diagnosis of pediatric CNS tumors; a single center experience. Neuro-Oncology, 2022, 24, i161-i161.	0.6	0
10	HGG-49. Gliomatosis cerebri in children: A collaborative report from the European Society for Pediatric Oncology (SIOPE). Neuro-Oncology, 2022, 24, i72-i73.	0.6	0
11	NFB-17. "Optic Pathway findings in children with Neurofibromatosis type-1 (NF-1). Neuro-Oncology, 2022, 24, i131-i131.	0.6	0
12	NFB-15. "Cognitive Impairments in Children and Adolescents with Neurofibromatosis". Neuro-Oncology, 2022, 24, i131-i131.	0.6	0
13	Thalassaemia. Lancet, The, 2022, 399, 2310-2324.	6.3	71
14	Genotype-phenotype association and variant characterization in Diamond-Blackfan anemia caused by pathogenic variants in <i>RPL35A</i>. Haematologica, 2021, 106, 1303-1310.	1.7	12
15	A review of psychosocial interventions targeting families of children with cancer. Palliative and Supportive Care, 2021, 19, 103-118.	0.6	27
16	CRISPR-Cas9 Gene Editing for Sickle Cell Disease and Î²-Thalassemia. New England Journal of Medicine, 2021, 384, 252-260.	13.9	939
17	Revisiting the nonâ€transfusionâ€dependent (NTDT) vs. transfusionâ€dependent (TDT) thalassemia classification 10 years later. American Journal of Hematology, 2021, 96, E54-E56.	2.0	28
18	Cognitive function of children and adolescent survivors of acute lymphoblastic leukemia: A metaâ€‘analysis. Oncology Letters, 2021, 21, 262.	0.8	13

#	Article	IF	Citations
19	Left ventricular deformation mechanics over time in patients with thalassemia major with and without iron overload. BMC Cardiovascular Disorders, 2021, 21, 81.	0.7	1
20	Delayedâ€onset severe neurotoxicity related to blinatumomab in an adolescent patient with refractory acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2021, 68, e29040.	0.8	5
21	Dental late effects of antineoplastic treatment on childhood cancer survivors: Radiographic findings. International Journal of Paediatric Dentistry, 2021, 31, 742-751.	1.0	5
22	Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in Î²-thalassemia: current evidence and future clinical development. Expert Review of Hematology, 2021, 14, 633-644.	1.0	13
23	PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum. Acta Neuropathologica, 2021, 142, 841-857.	3.9	36
24	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. Cancer Discovery, 2021, 11, 2764-2779.	7.7	110
25	Improving outcomes and quality of life for patients with transfusion-dependent Î²-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies. Expert Review of Hematology, 2021, 14, 897-909.	1.0	13
26	Recommendations for diagnosis and treatment of methemoglobinemia. American Journal of Hematology, 2021, 96, 1666-1678.	2.0	56
27	Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study. Lancet Oncology, The, 2021, 22, 1416-1426.	5.1	93
28	Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematology,the, 2021, 8, e22-e33.	2.2	82
29	Diamond-Blackfan Anemia: 2 Cases With a Twist. Journal of Pediatric Hematology/Oncology, 2021, 43, e539-e542.	0.3	0
30	The Prevalence of glucose dysregulations (GDs) in patients with Î²-thalassemias in different countries: A preliminary ICET-A survey. Acta Biomedica, 2021, 92, e2021240.	0.2	2
31	Isatuximab in Combination with Chemotherapy in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia (ISAKIDS): Interim Analysis. Blood, 2021, 138, 516-516.	0.6	4
32	Cerebral Sinovenous Thrombosis in Greek Children: A Single Centre Experience. Blood, 2021, 138, 4251-4251.	0.6	0
33	Summary of Joint European Hematology Association (EHA) and EuroBloodNet Recommendations on Diagnosis and Treatment of Methemoglobinemia. HemaSphere, 2021, 5, e660.	1.2	1
34	FISH-Guided Evaluation of Hyperdiploidy and Other Cytogenetic Abnormalities in Childhood Burkitt Lymphoma. Blood, 2021, 138, 1444-1444.	0.6	0
35	Adverse Events Following COVID-19 Vaccination in Transfusion-Dependent -Thalassemia Patients. Blood, 2021, 138, 2015-2015.	0.6	0
36	A Severe Mouse Model of Alpha-Thalassemia to Study Abnormal Iron Metabolism and Erythropoiesis, Hematopoietic Stem Cell Behavior and Development of a Gene Therapy Approach for Its Treatment. Blood, 2021, 138, 2012-2012.	0.6	0

#	Article	IF	Citations
37	Luspatercept Improves Quality of Life and Reduces Red Blood Cell Transfusion Burden in Patients with Non-Transfusion-Dependent Î²-Thalassemia in the BEYOND Trial. Blood, 2021, 138, 3081-3081.	0.6	4
38	Genotypic and Clinical Analysis of a Thalassemia Major Cohort: An Observational Study. Advances in Experimental Medicine and Biology, 2021, 1339, 65-76.	0.8	1
39	Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial. Lancet Haematology,the, 2020, 7, e469-e478.	2.2	39
40	Changing patterns in the epidemiology of Î²â€thalassemia. European Journal of Haematology, 2020, 105, 692-703.	1.1	122
41	Cytogenetically cryptic and fish negative PML/RARA rearrangement in acute promyelocytic leukemia detected by RT-PCR. Leukemia and Lymphoma, 2020, 61, 3526-3528.	0.6	3
42	A Case Series of BCOR Sarcomas With a New Splice Variant of BCOR/CCNB3 Fusion Gene. In Vivo, 2020, 34, 2947-2954.	0.6	7
43	Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study. Experimental Hematology and Oncology, 2020, 9, 20.	2.0	9
44	Longitudinal evaluation of eltrombopag in paediatric acquired severe aplastic anaemia. British Journal of Haematology, 2020, 190, e157-e159.	1.2	8
45	A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent Î²-Thalassemia. New England Journal of Medicine, 2020, 382, 1219-1231.	13.9	177
46	Diamondâ€“Blackfan anaemia: understanding an old disease. British Journal of Haematology, 2020, 190, 14-15.	1.2	4
47	CONCISE REVIEW ON THE FREQUENCY, MAJOR RISK FACTORS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA (HCC) IN Î²-THALASSEMIAS: PAST, PRESENT AND FUTURE PERSPECTIVES. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020006.	0.5	18
48	Longitudinal Effect of Luspatercept Treatment on Iron Overload and Iron Chelation Therapy (ICT) in Adult Patients (Pts) with Î²-Thalassemia in the Believe Trial. Blood, 2020, 136, 47-48.	0.6	8
49	Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent Î²-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells. Blood, 2020, 136, 3-4.	0.6	34
50	Sustained Reductions in Red Blood Cell (RBC) Transfusion Burden and Events in Î²-Thalassemia with Luspatercept: Longitudinal Results of the Believe Trial. Blood, 2020, 136, 45-46.	0.6	8
51	The Effect of Treatment and Bone Metabolic Factors on Fracture Incidence in Patients with Thalassemia-Induced Osteoporosis: An Observational Study. Current Drug Therapy, 2020, 15, 381-388.	0.2	0
52	Children Diagnosed with Acute Leukemia of Ambiguous Lineage (ALAL) Benefit from Acute Myeloid Leukemia (AML) Treatment Protocols: A Retrospective Analysis from a Single Center. Blood, 2020, 136, 32-32.	0.6	0
53	An Epidemiological, Retrospective Cross-Sectional Study to Capture the Real-World Complication Burden, and Disease Management Paradigms in Transfusion-Dependent Beta-Thalassemia Adults in Greece: Interim Results of the Ulysses Study. Blood, 2020, 136, 5-6.	0.6	1
54	Quality of life in patients with Î²â€thalassemia: A prospective study of transfusionâ€dependent and nonâ€transfusionâ€dependent patients in Greece, Italy, Lebanon, and Thailand. American Journal of Hematology, 2019, 94, E261-E264.	2.0	21

#	Article	IF	Citations
55	High resolution Chromosomal Microarray Analysis (CMA) enhances the genetic profile of pediatric B-cell Acute Lymphoblastic Leukemia patients. Leukemia Research, 2019, 83, 106177.	0.4	6
56	Does splenectomy influence the development of Hypothyroidism in Transfusion Dependent Thalassemia Patients? A retrospective study.. Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019064.	0.5	1
57	Development of a multidisciplinary clinic of neurofibromatosis type 1 and other neurocutaneous disorders in Greece. A 3-year experience. Postgraduate Medicine, 2019, 131, 445-452.	0.9	12
58	Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand?. Journal of Neuro-Oncology, 2019, 145, 177-184.	1.4	36
59	Antibody persistence 5Âyears after a 13-valent pneumococcal conjugate vaccine in asplenic patients with Î²-thalassemia: assessing the need for booster. Annals of Hematology, 2019, 98, 775-779.	0.8	5
60	A prospective study on the epidemiology and clinical significance of viral respiratory infections among pediatric oncology patients. Pediatric Hematology and Oncology, 2019, 36, 173-186.	0.3	12
61	Late effects of chemo and radiation treatment on dental structures of childhood cancer survivors. A systematic review and metaâ€analysis. Head and Neck, 2019, 41, 3422-3433.	0.9	20
62	National registry of hemoglobinopathies in Greece: updated demographics, current trends in affected births, and causes of mortality. Annals of Hematology, 2019, 98, 55-66.	0.8	48
63	Validation of a patientâ€reported outcomes symptom measure for patients with nontransfusionâ€dependent thalassemia (NTDTâ€PRO^{Â©}). American Journal of Hematology, 2019, 94, 177-183.	2.0	7
64	Renal function abnormalities and deferasirox. The Lancet Child and Adolescent Health, 2019, 3, 2-3.	2.7	5
65	Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial. Blood, 2019, 134, 2245-2245.	0.6	7
66	Evaluating Luspatercept Responders in the Phase 3, Randomized, Double-Blind, Placebo-Controlled BELIEVE Trial of Luspatercept in Adult Beta-Thalassemia Patients (Pts) Who Require Regular Red Blood Cell (RBC) Transfusions. Blood, 2019, 134, 3545-3545.	0.6	3
67	Sickle-Cell Disease in Greece: Patient Reported Outcomes Related to Clinical Complications, Treatment Choices and Attitudes, Beliefs and Trends Affecting Potential Participation in Clinical Trials - a Greek National Multicentric Study. Blood, 2019, 134, 4838-4838.	0.6	2
68	Bone Metabolism Markers in Thalassemia Major-Induced Osteoporosis: Results from a Cross-Sectional Observational Study. Current Molecular Medicine, 2019, 19, 335-341.	0.6	7
69	Giant intracranial congenital hemangiopericytoma/solitary fibrous tumor: A case report and literature review. , 2019, 10, 75.		4
70	Neutropenia in Children Treated with Deferiprone or Deferasirox: A Report of the Largest Randomized Trial of Oral Chelators in Transfusion-Dependent Pediatric Patients. Blood, 2019, 134, 3552-3552.	0.6	2
71	Pl<scp>GF</scp> and <scp>sF</scp>ltâ€1 levels in patients with nonâ€transfusionâ€dependent thalassemia: Correlations with markers of iron burden and endothelial dysfunction. European Journal of Haematology, 2018, 100, 630-635.	1.1	9
72	High Yield of Pathogenic Germline Mutations Causative or Likely Causative of the Cancer Phenotype in Selected Children with Cancer. Clinical Cancer Research, 2018, 24, 1594-1603.	3.2	52

#	Article	IF	Citations
73	International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia. Blood, 2018, 132, 264-276.	0.6	70
74	Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study. Blood, 2018, 131, 263-265.	0.6	45
75	Long-term safety of deferiprone treatment in children from the Mediterranean region with beta-thalassemia major: the DEEP-3 multi-center observational safety study. Haematologica, 2018, 103, e1-e4.	1.7	14
76	Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias. Health and Quality of Life Outcomes, 2018, 16, 216.	1.0	15
77	The role of biphosphonates in the management of thalassemia-induced osteoporosis: a systematic review and meta-analysis. Hormones, 2018, 17, 153-166.	0.9	9
78	Targeted next generation sequencing for the diagnosis of patients with rare congenital anemias. European Journal of Haematology, 2018, 101, 297-304.	1.1	27
79	Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease. Blood, 2018, 132, 469-483.	0.6	70
80	Optimising management of deferasirox therapy for patients with transfusionâ€dependent thalassaemia and lowerâ€risk myelodysplastic syndromes. European Journal of Haematology, 2018, 101, 272-282.	1.1	16
81	The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions. Blood, 2018, 132, 163-163.	0.6	11
82	Phenotypes of Diamond Blackfan Anemia Patients with RPL35A Haploinsufficiency Due to 3q29 Deletion Compared with RPL35A Single Nucleotide Variants or Small Insertion/Deletions. Blood, 2018, 132, 3854-3854.	0.6	3
83	Hepatitis C Virus Infection, but Not Hepatic Iron Overload Is the Dominant Risk Factor for the Manifestation of Hepatocellular Carcinoma Among Greek Thalassemic Patients. Blood, 2018, 132, 2347-2347.	0.6	2
84	Second malignant neoplasms in children and adolescents treated for blood malignancies and solid tumors: A single-center experience of 15 years. Indian Journal of Medical and Paediatric Oncology, 2018, 39, 483.	0.1	0
85	Increased Age-Related B-Cells in Patients with Aplastic Anemia. Blood, 2018, 132, 5099-5099.	0.6	0
86	Understanding the Role of Hyperdiploidy in Burkitt Lymphoma of Childhood: Biological and Clinical Correlates. Blood, 2018, 132, 5296-5296.	0.6	0
87	Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. Journal of Neuro-Oncology, 2017, 132, 255-266.	1.4	42
88	New filmâ€coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lowerâ€risk MDS: Results of the randomized, phase II ECLIPSE study. American Journal of Hematology, 2017, 92, 420-428.	2.0	66
89	Treatment of chronic hepatitis C with directâ€acting antivirals in patients with Î²â€thalassaemia major and advanced liver disease. British Journal of Haematology, 2017, 178, 130-136.	1.2	23
90	Iron overload across the spectrum of nonâ€transfusionâ€dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions. British Journal of Haematology, 2017, 176, 288-299.	1.2	43

#	Article	IF	Citations
91	The Greek Registry of Shwachman Diamondâ€Syndrome: Molecular and clinical data. Pediatric Blood and Cancer, 2017, 64, e26630.	0.8	12
92	Recommendations regarding splenectomy in hereditary hemolytic anemias. Haematologica, 2017, 102, 1304-1313.	1.7	138
93	Electrophysiological assessment for early detection of retinal dysfunction in Î²-thalassemia major patients. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 1349-1358.	1.0	9
94	Serum Levels of S100b and NSE Proteins in Patients with Non-Transfusion-Dependent Thalassemia as Biomarkers of Brain Ischemia and Cerebral Vasculopathy. International Journal of Molecular Sciences, 2017, 18, 2724.	1.8	24
95	Quality of Life in Patients with Î²-Thalassemia: Transfusion Dependent Versus Non-Transfusion Dependent. Blood, 2017, 130, 751-751.	0.6	1
96	Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes. Drug Design, Development and Therapy, 2016, Volume 10, 4073-4078.	2.0	15
97	Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study. Blood Cells, Molecules, and Diseases, 2016, 57, 23-29.	0.6	24
98	Complex preimplantation genetic diagnosis for beta-thalassaemia, sideroblastic anaemia, and human leukocyte antigen (HLA)-typing. Systems Biology in Reproductive Medicine, 2016, 62, 69-76.	1.0	10
99	Development of a new disease severity scoring system for patients with non-transfusion-dependent thalassemia. European Journal of Internal Medicine, 2016, 28, 91-96.	1.0	14
100	Palliative and end-of-life care for children with diffuse intrinsic pontine glioma: results from a London cohort study and international survey. Neuro-Oncology, 2016, 18, 582-588.	0.6	25
101	New Film-Coated Tablet Formulation of Deferasirox Is Well Tolerated in Patients with Thalassemia or MDS: Results of the Randomized, Phase II E.C.L.I.P.S.E. Study. Blood, 2016, 128, 1285-1285.	0.6	4
102	The Changing Landscape of Treatment in Pediatric Aplastic Anemia; A Single Institution's Experience. Blood, 2016, 128, 5082-5082.	0.6	1
103	Acute Leukemia of Ambiguous Lineage: A Comprehensive Survival Analysis Enables Designing New Treatment Strategies. Blood, 2016, 128, 584-584.	0.6	2
104	Improved Patient-Reported Outcomes with a Film-Coated Versus Dispersible Tablet Formulation of Deferasirox: Results from the Randomized, Phase II E.C.L.I.P.S.E. Study. Blood, 2016, 128, 850-850.	0.6	5
105	Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study. Blood, 2016, 128, 852-852.	0.6	10
106	Effects of teriparatide retreatment in a patient with Î²â€thalassemia major. Transfusion, 2015, 55, 2905-2910.	0.8	14
107	Hb Souli, a 6â€‰bp In-Frame Deletion on theHBA2Gene (HBA2: c.[41-46delCCTGGG]) Leads toÎ±-Thalassemia Intermedia, When inTransto a SingleÎ±-Globin Gene Deletion. Hemoglobin, 2015, 39, 55-57.	0.4	2
108	Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload. Blood, 2015, 125, 3868-3877.	0.6	67

#	Article	IF	Citations
109	Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when <scp>MRI</scp> is unavailable in patients with nonâ€transfusionâ€dependent thalassaemia. British Journal of Haematology, 2015, 168, 284-290.	1.2	50
110	Acute Leukemias of Ambiguous Lineage; Study on 247 Pediatric Patients. Blood, 2015, 126, 252-252.	0.6	4
111	Efficacy and Safety of Deferasirox Across Underlying Non-Transfusion-Dependent Thalassemia Syndromes: 1-Year Results from the Thetis Study. Blood, 2015, 126, 3366-3366.	0.6	0
112	Correlation of Hepatocyte Iron Score and Liver Iron Ratio with Alanine Aminotransferase in Patients with Beta Thalassemia Receiving Iron Chelation Therapy for at Least 3 Years. Blood, 2015, 126, 2156-2156.	0.6	0
113	Optimizing Iron Chelation Therapy with Deferasirox for Non-Transfusion-Dependent Thalassemia Patients: 1-Year Results from the Phase IV, Open-Label Thetis Study. Blood, 2015, 126, 2153-2153.	0.6	7
114	Evaluation of Intracranial Cerebral Blood Flow Velocities in Splenectomised and Non-Splenectomised Patients with Î²-Thalassemia Intermedia Using Transcranial Doppler Sonography. In Vivo, 2015, 29, 501-4.	0.6	2
115	Pituitary stalk lesion in a 13-year-old female. Journal of Pediatric Endocrinology and Metabolism, 2014, 27, 359-62.	0.4	4
116	Clinical phenotype and genetic analysis of RPS19, RPL5, and RPL11 genes in Greek patients with Diamond Blackfan Anemia. Pediatric Blood and Cancer, 2014, 61, 2249-2255.	0.8	13
117	Antigen-Specific B-Cell Response to 13-Valent Pneumococcal Conjugate Vaccine in Asplenic Individuals With Â-Thalassemia Previously Immunized With 23-Valent Pneumococcal Polysaccharide Vaccine. Clinical Infectious Diseases, 2014, 59, 862-865.	2.9	26
118	Current approach to iron chelation in children. British Journal of Haematology, 2014, 165, 745-755.	1.2	31
119	Approaching low liver iron burden in chelated patients with nonâ€transfusionâ€dependent thalassemia: the safety profile of deferasirox. European Journal of Haematology, 2014, 92, 521-526.	1.1	17
120	Successful management of a small infant with Kasabachâ€“Merritt phenomenon using vincristine. Blood Coagulation and Fibrinolysis, 2014, 25, 777-779.	0.5	2
121	Are We United Enough to Come Down with Common Charter of Demands: The Health Professionalsâ€™ Perspective. Thalassemia Reports, 2014, 4, 4883.	0.1	0
122	Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Annals of Hematology, 2013, 92, 1485-1493.	0.8	64
123	Deferasirox demonstrates a doseâ€dependent reduction in liver iron concentration and consistent efficacy across subgroups of nonâ€transfusionâ€dependent thalassemia patients. American Journal of Hematology, 2013, 88, 503-506.	2.0	16
124	Abnormal myocardial perfusionâ€“fibrosis pattern in sickle cell disease assessed by cardiac magnetic resonance imaging. International Journal of Cardiology, 2013, 166, e75-e76.	0.8	12
125	Impact Of Liver Iron Overload On Myocardial T2* Response In Transfusion-Dependent Thalassemia Major Patients Treated With Deferasirox For Up To 3 Years. Blood, 2013, 122, 1016-1016.	0.6	3
126	Deferasiroxâ€“Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION). Blood, 2013, 122, 2257-2257.	0.6	5

#	Article	IF	Citations
127	Investigation of FANCA mutations in Greek patients. Anticancer Research, 2013, 33, 3369-74.	0.5	0
128	Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with Â-thalassemia major. Haematologica, 2012, 97, 842-848.	1.7	122
129	A national registry of haemoglobinopathies in Greece: Deducted demographics, trends in mortality and affected births. Annals of Hematology, 2012, 91, 1451-1458.	0.8	72
130	Frameshift mutation in p53 regulatorRPL26is associated with multiple physical abnormalities and a specific pre-ribosomal RNA processing defect in diamond-blackfan anemia. Human Mutation, 2012, 33, 1037-1044.	1.1	135
131	Adhesion molecules and highâ€sensitivity Câ€reactive protein levels in patients with sickle cell betaâ€thalassaemia. European Journal of Clinical Investigation, 2012, 42, 27-33.	1.7	19
132	Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA). Blood, 2012, 120, 3258-3258.	0.6	3
133	Concomitant Medications and Gastrointestinal Events in Thalassemia and MDS Patients Receiving Deferasirox for Transfusional Iron Overload: Data From the EPIC Study. Blood, 2012, 120, 5182-5182.	0.6	3
134	Occurrence of Neoplastic Diseases in a Large Cohort of Thalassemic Patients in Greece. Blood, 2012, 120, 3264-3264.	0.6	0
135	Iron chelation therapy in thalassemia major: A systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood Cells, Molecules, and Diseases, 2011, 47, 166-175.	0.6	50
136	Pulmonary Embolism After Snake Bite in a Child With Diamond-Blackfan Anemia. Journal of Pediatric Hematology/Oncology, 2011, 33, 68-70.	0.3	5
137	Survival in a large cohort of Greek patients with transfusion-dependent beta thalassaemia and mortality ratios compared to the general population. European Journal of Haematology, 2011, 86, 332-338.	1.1	62
138	Impact of magnetic resonance imaging on cardiac mortality in thalassemia major. Journal of Magnetic Resonance Imaging, 2011, 34, 56-59.	1.9	40
139	Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood, 2011, 118, 884-893.	0.6	181
140	Continued improvement in myocardial T2* over two years of deferasirox therapy in Â-thalassemia major patients with cardiac iron overload. Haematologica, 2011, 96, 48-54.	1.7	70
141	Deferasirox Significantly Reduces Liver Iron Concentration In Non-Transfusion-Dependent Thalassemia Patients with Iron Overload: Results From the 1-Year Randomized, Double-Blind, Placebo-Controlled Phase II THALASSA Study. Blood, 2011, 118, 902-902.	0.6	2
142	No Mutations in the RPL11 Gene Detected in Greek Patients with Diamond Blackfan Anemia. Blood, 2011, 118, 4856-4856.	0.6	0
143	Deferasirox Safety Profile in Patients with Transfusion-Dependent Anaemias:Results From the Interim Analysis of a Hellenic Study,. Blood, 2011, 118, 3183-3183.	0.6	1
144	Longitudinal Changes in Iron Overload Parameters and Iron Chelation Therapy in Young Patients with Thalassemia Major,. Blood, 2011, 118, 3202-3202.	0.6	0

#	Article	IF	Citations
145	Efficacy of deferasirox in reducing and preventing cardiac iron overload in Î²-thalassemia. Blood, 2010, 115, 2364-2371.	0.6	168
146	Novel TMPRSS6 mutations associated with iron-refractory iron deficiency anemia (IRIDA). Human Mutation, 2010, 31, E1390-E1405.	1.1	56
147	Deferasirox administration for the treatment of nonâ€transfusional iron overload in patients with thalassaemia intermedia. British Journal of Haematology, 2010, 151, 504-508.	1.2	27
148	Cardiac magnetic resonance in transfusion dependent thalassaemia: assessment of iron load and relationship to left ventricular ejection fraction. British Journal of Haematology, 2010, 151, 397-401.	1.2	11
149	Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica, 2010, 95, 557-566.	1.7	260
150	Cystatin C levels in patients with Î²-thalassemia during deferasirox treatment. Blood Cells, Molecules, and Diseases, 2010, 44, 152-155.	0.6	23
151	Continued Improvement and Normalization of Myocardial T2* In Patients with Î²-thalassemia Major Treated with Deferasirox (ExjadeÂ®) for up to 3 Years. Blood, 2010, 116, 4276-4276.	0.6	8
152	Assessment of iron distribution between liver, spleen, pancreas, bone marrow, and myocardium by means of R2 relaxometry with MRI in patients with Î²â€thalassemia major. Journal of Magnetic Resonance Imaging, 2009, 29, 853-859.	1.9	81
153	A novel mutation in the G4.5 (TAZ) gene in a Greek patient with Barth syndrome. Blood Cells, Molecules, and Diseases, 2009, 42, 262-264.	0.6	9
154	Soluble endothelial adhesion molecules and inflammation markers in patients with Î²-thalassemia intermedia. Blood Cells, Molecules, and Diseases, 2009, 43, 230-234.	0.6	33
155	Efficacy and Safety of Deferasirox (ExjadeÂ®) in Î²-Thalassemia Patients with Myocardial Siderosis: 2-Year Results From the EPIC Cardiac Sub-Study.. Blood, 2009, 114, 4062-4062.	0.6	4
156	Efficacy and Safety of Deferasirox (ExjadeÂ®) in Patients with Î²-Thalassemia Major Treated for up to 5 Years.. Blood, 2009, 114, 4063-4063.	0.6	5
157	Randomized Phase II Study Evaluating the Efficacy and Safety of Deferasirox in Non-Transfusion-Dependent Thalassemia Patients with Iron Overload.. Blood, 2009, 114, 5111-5111.	0.6	1
158	Improvement in Right Ventricular Function Following 1 Year of Deferasirox Therapy in Patients with Î²-Thalassemia.. Blood, 2009, 114, 5106-5106.	0.6	1
159	History of Hepatitis B or C Does Not Affect Safety and Efficacy of Deferasirox (ExjadeÂ®) in Thalassemia Major Patients: Sub-Analysis of the EPIC Trial.. Blood, 2009, 114, 5107-5107.	0.6	0
160	Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion. Nephrology Dialysis Transplantation, 2008, 23, 3874-3879.	0.4	99
161	Efficacy and Safety of Deferasirox (ExjadeÂ®) in Reducing Cardiac Iron in Patients with Î²-Thalassemia Major: Results from the Cardiac Substudy of the EPIC Trial. Blood, 2008, 112, 3873-3873.	0.6	12
162	Efficacy and Safety of Deferasirox (ExjadeÂ®) in Patients with Transfusion- Dependent Anemias: 1-Year Results from the Large, Prospective, Multicenter EPIC Study. Blood, 2008, 112, 3875-3875.	0.6	7

#	Article	IF	Citations
163	Efficacy and Safety of Once-Daily, Oral Iron Chelator Deferasirox (ExjadeÂ®) in a Large Group of Regularly Transfused Patients with Î²-Thalassemia Major. Blood, 2008, 112, 3878-3878.	0.6	12
164	Effect of Deferasirox (ExjadeÂ®) on Labile Plasma Iron Levels in Heavily Iron-Overloaded Patients with Transfusion-Dependent Anemias Enrolled in the Large-Scale, Prospective 1-Year EPIC Trial. Blood, 2008, 112, 3881-3881.	0.6	14
165	Deferasirox (ExjadeÂ®) in Pediatric Patients with Î²-Thalassemia: Update of 4.7-Year Efficacy and Safety from Extension Studies. Blood, 2008, 112, 3883-3883.	0.6	5
166	Efficacy and Safety of Deferasirox (ExjadeÂ®) with up to 4.5 Years of Treatment in Patients with Thalassemia Major: A Pooled Analysis. Blood, 2008, 112, 5411-5411.	0.6	9
167	Switching from Deferoxamine (DesferalÂ®, DFO) to Deferasirox (ExjadeÂ®) Maintains Effective Control of Iron Levels in Patients with Thalassemia Major (TM). Blood, 2008, 112, 5416-5416.	0.6	0
168	Transfusion History, Iron Chelation Practices and Status of Iron Overload across Various Transfusion-Dependent Anemias: Data from the Large- Scale, Prospective, 1-Year EPIC Trial. Blood, 2008, 112, 3880-3880.	0.6	0
169	Treatment of Thalassemia With Hydroxyurea: An Indispensable Alternative Therapy. Journal of Pediatric Hematology/Oncology, 2007, 29, 729-730.	0.3	5
170	Iron Chelation Therapy in the Context of the Latest Iron Science. Seminars in Hematology, 2007, 44, S7-S11.	1.8	2
171	Iron chelation treatment with combined therapy with deferiprone and deferioxamine: A 12-month trial. Blood Cells, Molecules, and Diseases, 2006, 36, 21-25.	0.6	75
172	A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood, 2006, 107, 3455-3462.	0.6	636
173	Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thrombosis and Haemostasis, 2006, 96, 488-491.	1.8	281
174	The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica, 2006, 91, 809-12.	1.7	116
175	A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica, 2006, 91, 1241-3.	1.7	61
176	Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thrombosis and Haemostasis, 2006, 96, 488-91.	1.8	86
177	Combined Therapy with Deferoxamine and Deferiprone. Annals of the New York Academy of Sciences, 2005, 1054, 175-182.	1.8	26
178	Sustained response to interferon alpha-2a in thalassemic patients with chronic hepatitis C. A prospective 8-year follow-up study. Haematologica, 2005, 90, 129-31.	1.7	9
179	Clinical Response and Adverse Events in Young Patients with Sickle Cell Disease Treated with Hydroxyurea. Pediatric Hematology and Oncology, 2004, 21, 335-342.	0.3	14
180	Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion. Haematologica, 2003, 88, 1423-5.	1.7	35